Rituximab is given at a weekly dose of 375 mg/m2 over four weeks, based on lymphoma management guidelines, although further immunosuppression is guaranteed in failed ADAMTS13 activity level normalization [57]. The gene discussed is ADAMTS13; the disease is lymphoma.